AstraZeneca has announced its five-year investment plan worth of $220 million in Vietnam.
The committed fund is said to help the biopharmaceutical giant further develop and enhance the quality of healthcare products and services to Vietnamese patients.
The company will also provide hundreds of jobs in the fields of biomedical and medical sciences, as well as medical sales and marketing through its partnerships with other businesses.
Part of AstraZeneca’s commitment includes the implementation of the Young Health Programme to improve the management and control of non-communicable diseases.
Accordingly, AstraZeneca, Plan International, the National Youth Centre and the Hanoi Centre for Disease Prevention and Control will work together to empower young people and their communities to make healthy choices in diet, exercise and lifestyle.
According to Leif Johannson, chairman of AstraZeneca, its investment in Vietnam will help lift the country’s healthcare capability to world-class levels and reach the goals of the UN 2030 Agenda for Sustainable Development.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas of oncology, cardiovascular, renal and metabolism and respiratory.